MassMutual Private Wealth & Trust’s Esperion Therapeutics ESPR Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,050	Closed	-$6.48K	–	2390
2026 Q2	$6.48K	Sell	2,050 -450	-18%	-$1.26K	﹤0.01%	1587
2026 Q1	$6.85K	Buy	2,500 +1,268	+103%	+$4.01K	﹤0.01%	1533
2025 Q4	$4.56K	Buy	1,232 +492	+66%	+$1.59K	﹤0.01%	1716
2025 Q3	$1.96K	Buy	+740	New	+$1.43K	﹤0.01%	1992
2025 Q2	–	Sell	-1,394	Closed	-$2.01K	–	2397
2025 Q1	$2.01K	Buy	+1,394	New	+$2.57K	﹤0.01%	1914
2022 Q4	–	Sell	-40	Closed	–	–	1700
2022 Q3	$0	Buy	+40	New	+$275	﹤0.01%	1669

MassMutual Private Wealth & Trust's ESPR Position: Q3 2026 in Review

MassMutual Private Wealth & Trust sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 2,050 shares — an estimated $6.48K sold.

MassMutual Private Wealth & Trust first reported a position in ESPR in Q3 2022 and held it in 6 quarters. The position peaked at $6.85K in Q1 2026. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

MassMutual Private Wealth & Trust reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
MassMutual Private Wealth & Trust sold 2,050 Esperion Therapeutics shares in Q3 2026, an estimated $6.48K.
MassMutual Private Wealth & Trust first reported a position in Esperion Therapeutics in Q3 2022 and held it in 6 quarters.
MassMutual Private Wealth & Trust's Esperion Therapeutics position peaked at $6.85K in Q1 2026.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.